PlainRecalls
FDA Drug Moderate Class II Completed

Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-90

Reported: June 26, 2024 Initiated: May 17, 2024 #D-0562-2024

Product Description

Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-90

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Details

Units Affected
165,678, 90-count bottles
Distribution
Nationwide in the USA
Location
Berlin, CT

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-90. Recalled by Breckenridge Pharmaceutical, Inc. Units affected: 165,678, 90-count bottles.
Why was this product recalled?
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Which agency issued this recall?
This recall was issued by the FDA Drug on June 26, 2024. Severity: Moderate. Recall number: D-0562-2024.